Mode
Text Size
Log in / Sign up
N/A N=21 Randomized Double-blind Treatment

Evaluation of The Clinical Acceptance of Soft Contact Lenses for Myopia Control

Myopia

Enrolled (actual)
21
Serious AEs
0.0%
Results posted
Aug 2024
Primary outcome: Primary: Overall Vision Satisfaction — 87.7; 79.7; 71.8 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
omafilcon A control lens (Device); omafilcon A test lens 1 (Device); omafilcon A test lens 2 (Device)
Age
Pediatric · 10+ yrs
Sex
All
Sponsor
CooperVision, Inc.
Primary completion
Mar 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Overall Vision Satisfaction
87.7; 79.7; 71.8
PRIMARY
Habitual Daily Wearing Time
7.9; 8.1; 7.8
SECONDARY
Visual Acuity
0.06; 0.08; 0.10
SECONDARY
Overall Visual Satisfaction During the Use of iPad With White Screen
90.8; 90.8; 85.1
SECONDARY
Visual Satisfaction During the Use of Ipad With White Screen- How Clear is the Close-up Vision.
90.7; 90.0; 84.4
SECONDARY
Visual Satisfaction During the Use of iPad With Black Screen- How Happy the Vision is.
85.4; 86.8; 80.0
SECONDARY
Visual Satisfaction During the Use of Ipad With Black Screen- How Clear is the Close-up the Vision is.
85.3; 87.5; 79.2

Summary

The main objective of the study was to evaluate the clinical acceptance of soft contact lenses for Myopia control.

Eligibility Criteria

Inclusion Criteria

  • Age 10 to 16 years;
  • Spectacle refraction: -0.75 to -6.00D spherical equivalent, maximum anisometropia 1.25D, cylinder up to -1.00DC
  • Best corrected visual acuity of at least 20/25 in each eye.
  • Parents/guardians and participant have read and understood the Participant Information Sheet;
  • Parents/guardians and participant have read, signed and dated the Informed Consent;
  • Have normal eyes with the exception of the need for visual correction;
  • Be willing and able to adhere to the instructions set in the clinical protocol and maintain the appointment schedule.

Exclusion Criteria

  • Ocular anterior segment infection, inflammation, abnormality, or active disease that would contraindicate contact lens wear;
  • Newly prescribed use of some systemic or ocular medications for which contact lens wear could be contraindicated as determined by the investigator;
  • Monocular participants (only one eye with functional vision) or participants fit with only one lens;
  • Subjects with slit lamp findings greater than grade 1 (e.g. edema, infiltrates, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival, anterior segment inflammation) as per ISO 11980, any previous history or signs of a contact lens related corneal inflammatory event (past corneal ulcers), or any other ocular abnormality that may contraindicate contact lens wear at the enrolment visit;
  • History of herpetic keratitis, ocular surgery or irregular cornea;
  • Enrolment of the family members of the investigator, family members of the investigator's staff, or individuals living in the households of these individuals.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04709237). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search